Critical Contrast: Nuvo Pharmaceuticals (OTCMKTS:MRVFF) vs. Bolt Biotherapeutics (NASDAQ:BOLT)

Nuvo Pharmaceuticals (OTCMKTS:MRVFFGet Free Report) and Bolt Biotherapeutics (NASDAQ:BOLTGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.


This table compares Nuvo Pharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals 20.88% -1,996.22% 14.25%
Bolt Biotherapeutics -990.43% -47.56% -35.64%

Risk and Volatility

Nuvo Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Earnings & Valuation

This table compares Nuvo Pharmaceuticals and Bolt Biotherapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvo Pharmaceuticals $54.98 million 0.20 -$25.70 million ($0.12) -8.16
Bolt Biotherapeutics $5.73 million 7.16 -$88.10 million ($1.89) -0.57

Nuvo Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

73.6% of Bolt Biotherapeutics shares are held by institutional investors. 7.0% of Nuvo Pharmaceuticals shares are held by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Nuvo Pharmaceuticals and Bolt Biotherapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvo Pharmaceuticals 0 0 0 0 N/A
Bolt Biotherapeutics 0 0 2 0 3.00

Bolt Biotherapeutics has a consensus price target of $7.00, indicating a potential upside of 548.15%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Nuvo Pharmaceuticals.


Bolt Biotherapeutics beats Nuvo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Nuvo Pharmaceuticals

(Get Free Report)

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with's FREE daily email newsletter.